FDA approves inclusion of data from safety outcomes trial in the Tresiba(R) label
The data showed that Tresiba® (insulin degludec injection) U-100 had no increased risk of MACE compared to insulin glargine U-100 in patients with type 2 diabetes and ASCVD1
Tresiba® U-100 becomes the first and only long-acting insulin to have d... Biopharmaceuticals, Endocrinology, Cardiology, FDA Novo Nordisk, Tresiba, insulin degludec, insulin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Insulin | Lantus | Pharmaceuticals